Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC
October 21st 2018The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.